IFNA1 and autoimmune disease: Notably, administering the PPT1 inhibitor hexadecylsulfonylfluoride (HDSF) to both healthy volunteers and SLE patients reduces IFNα production ex vivo, underscoring its therapeutic potential for autoimmune diseases.